

Amendments to the Specification:

On page 1, after the title, please insert the following paragraph:

The present application is a continuation application of U.S. Application No. 09/646,785, filed February 16, 2001, which is a U.S. National Phase Application of International Application PCT/JP99/01448, filed March 23, 1999, which claims the benefit of Japanese Patent Application No. P1998-095448, filed March 24, 1998, all of which are herein incorporated by reference in their entirety

Please replace the paragraph on page 15, lines 5-14 with the following amended paragraph:

Also, the amino acid sequence of SDF-1, which is a ligand binding to CXCR4, has already been known. There are two types of SDF-1 differing in the length of amino acid sequence, *i.e.*, SDF-1- α and SDF-1- β . Specifically, the amino acid sequence of human SDF-1- α is set forth in SEQ ID NO: 5 and its base sequence in SEQ ID NO: 6 (base positions 474-740). Human SDF-1- β [~~(SEQ ID NO: 9)~~] is derived from human SDF-1- α by appending four amino acid residues, Arg Phe Lys Met (SEQ ID NO: 9), to a C-terminus thereof.

Please replace the paragraph on page 15, lines 15-22 with the following amended paragraph:

The amino acid sequence of murine SDF-1- α is set forth in SEQ ID NO: 7 and its base sequence in SEQ ID NO: 8 (base positions 82-348). Murine SDF-1- β [~~(SEQ ID NO: 10)~~] is derived from murine SDF-1- α by appending four amino acid residues, Arg Leu Lys Met (SEQ ID NO: 10), to a C-terminus thereof. For human and murine SDF-1's, the sequence of from the 1st amino acid (Met) to the 21st amino acid (Gly) is a signal sequence.

Please delete the previous sequence listing and substitute therefore new pages 1-8 which comprise the paper copy of the corrected Sequence Listing and renumber them accordingly.